DDX3X and neoplasm: Next-generation compounds that target the ATPase activity of DDX3 were also synthesized such as NZ51 and RK-33, the latter widely characterised as an anti-tumour compound, with activity against multiple tumour types (Bol et al., 2015a; Xie et al., 2015).